iShares MBS ETF vs Rocket Lab USA Inc — how do they compare? iShares MBS ETF trades at $89.66 (market cap $35.41B), while Rocket Lab USA Inc trades at $67.55 (market cap $43.74B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and Rocket Lab USA Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Rocket Lab USA Inc for 29 Days on average.
| MBB | RKLB | |
|---|---|---|
Market Cap | $35.41B | $43.74B |
Volume | 5,388,525 | 22,892,581 |
Sector | Fixed Income | Industrials |
52-Week High | $96.91 | $150.23 |
52-Week Low | $89.09 | $39.48 |
Typical Hold Time | 96 Days | 29 Days |
Enterprise Value | — | $41.57B |
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.54, up 0.36% on the day but showing a bearish technical signal overall. The ETF has faced significant short interest growth of 98.3% in September 2026, reaching 6.57 million shares, and recently hit a 52-week low. Recent news highlights concerns over intermediate duration risk amid potential rate hikes, though institutional buying from firms like Corient Private Wealth and Baird Financial Group provides some support. Key technical indicators show oversold conditions on the 12-day RSI but strong selling pressure from moving averages.
The outlook for MBB remains cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. While dividend payments offer income, rising rates and inflation pressures pose downside risks. Analyst sentiment is neutral to bearish, with the ETF's performance heavily tied to Federal Reserve policy. Investors should weigh the high yield against duration risk in a tightening cycle.
Rocket Lab (RKLB) trades at $67.47, down 6.19% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of -$198.21M in 2025, though revenue grew to $601.80M. Recent news highlights a record 20-launch deal with Synspective, expanding the backlog past 100 missions, providing a positive catalyst amid ongoing losses and high valuation multiples.
The outlook remains speculative; strong analyst consensus (76% buy ratings) and a $107 price target suggest long-term growth potential from launch demand, but profitability challenges, cash burn, and competitive pressure from SpaceX pose significant risks. Investment hinges on execution toward Neutron rocket commercialization and path to sustained profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →